Neurosystemic
Medicine | Epigenetic Cancer Therapeutics
IntraTherapies addresses two of the
central and growing areas of disease which present increasing challenges to US
healthcare in the clinical categories of: Age-Related Neurodegenerative
Disorders & Late Stage Cancer Therapeutics.
PHYSICIAN MANAGED PERSONALIZED MEDICINE PROGRAMS
CATEGORY 1 | NEUROSYSTEMIC MEDICINE I AGE MANAGEMENT
THERAPEUTICS
This program is clinically directed toward to overall neuroendocrine support and
is based on the primary principles of neuroendocrinology within a clinical
program of personalized medicine. Neurosystemic Medicine addresses a spectrum of
predictive age–related degenerative disorders and central nervous system
functions with a group of Neurometabolic / Neuroendocrine regulating programs
for optimal neuro-systemic effect coupled with neuro protective factors
targeting cognitive function with potential neuroimmune benefits to support
healthy aging.
CATEGORY 2 | CANCER PREVENTIVE THERAPEUTICS
This program is clinically directed toward Enhanced Intracellular Genetic
Immunity (EIGI) via DNA Programmable Genetic Pharmacology.
CATEGORY 3 | EPIGENETIC CANCER THERAPEUTICS
IntraTherapies epigenetic programs are based on molecular cancer genetics and
DNA Programmable Genetic Pharmacology, in conjunction with targeted combination
therapies and pathway-specific programs targeted to achieve broader cancer
interventional effect with enhanced safety at the cellular level, absent adverse
impact on major cellular pathways. This approach, based on extensive human and
other mammal studies noted below, appears to result in notable reduction of
treatment toxicity levels across primary solid tumor cancer groups,
specifically, Breast, Colon, Prostate, Non Small Cell Lung, Renal, and Ovarian
cancer when further combined with Low Dose Metronomic Chemotherapy. All
IntraTherapies treatment programs are based on oncologist / hematologist
assessment of patient history, current treatment and health profile.
IECT - IntraTherapies Epigenetic Cancer Therapeutics is a Clinical Protocol
based on Molecular cancer genetics and DNA Programmable Genetic Pharmacology
directed toward inhibiting the Growth and Replication of Human Cancer Cells,
Administered as a Monotherapy or Conjunctively with Metronomic Low Dose
Chemotherapy.
Epigenetic Cancer Therapeutics is comprised of preventive and late stage cancer
interventional therapeutic programs focused on enhanced intracellular genetic
immunity. This is achieved by the integration of epigenetic programs combined
with specific standard of care oncology medications with clinically-validated
significantly reduced toxicity levels achieved via Metronomic Low Dose
Chemotherapy.
Provided as a monotherapy or within a conjunctive treatment protocol,
IntraTherapies Epigenetic Cancer Therapeutics has clinically demonstrated the
ability to inhibit the growth, replication and proliferation of human cancer
cells via DNA Methyltransferase Inhibitors. (See list of medical research
institutions and recognized peer-reviewed publications below)
Additional neurosystemic clinical objectives include the measurable achievement
of enhanced Quality of Life in managing Mood Disorders in Chronically ill
patients.
* Note: These statements are based on published medical research data from the
National Cancer Institute and other independent accredited medical institutions
in peer-reviewed oncology / hematology publications worldwide which include:
- Indiana University School of Medicine; Indiana University Cancer Center -
Departments of Surgery and Biochemistry/Molecular Biology
- Walther Oncology Center; Cancer Epigenetics Laboratory
- Spanish National Cancer Centre-Molecular Pathology Program
- Osaka University Graduate School of Medicine – Japan.
Published data referenced in this section appear in clinical oncology journals
including:
- Cancer Research / American Association for Cancer Research;
- Current Opinion in Oncology, Journal of Pharmacological Sciences
- Elsevier Cancer Letters,
- Molecular Cancer Therapeutics
- Modern Pathology
- JNCI - Journal of the National Cancer Institute
CATEGORY 4 | PAIN MANAGEMENT THERAPEUTICS
This program is clinically directed toward Interventional Regulation of
neuro-receptor and inflammation pathways for mediating chronic pain conditions
but also including degenerative osteo-arthritis, TMJ, post-traumatic surgical
pain as well as neck / back / spine disorders, chronic scoliosis, and extending
to overall Intra-systemic mediation of multi-source chronic pain within the
musculo-skeletal network.
CATEGORY 5 | MIGRAINE INTERVENTIONAL THERAPEUTICS
This program is clinically directed toward Neuro receptor channel modulation for
aura and non-aura-based chronic migraine and headache disorders.
CATEGORY 6 | SLEEP ENHANCEMENT THERAPEUTICS
This program is clinically directed toward targeted regulation of sleep
disturbances related to circadian and other neuro mechanisms to alleviate acute
and chronic insomnia as well as other inhibitors related to quality / continuity
of sleep, and lack of restorative sleep.
CATEGORY 7 | RHEUMATOLOGY AND IMMUNO-RESTORATIVE
THERAPEUTICS
This program is clinically directed to Rheumatoid Arthritis and all
Immuno-Degenerative, Autoimmune and inflammatory Disorders resulting from the
pathophysiologies of immuno-systemic compromise and chronic inflammation. This
regimen is further directed toward inflammatory diseases such as Fibromyalgia,
Lupus, Epstein-Barr, Chronic Fatigue Syndrome and the spectrum of approximately
105 immunity-related conditions.
CATEGORY 8 I NEUROOPTIC THERAPEUTICS
This program is clinically directed toward Vision Optimization and Vascular
Support for Long Term Eye Health.
CATEGORY 9 I SPORTS AND PERFORMANCE THERAPEUTICS
This program is clinically directed toward Optimization of Circulatory, Vascular
and Pulmonary Function with stabilization of Central and Sympathetic Nervous
System.
CATEGORY 10 | INTRACELLULAR DERMAL REGENERATIVE
THERAPEUTICS
This program is clinically directed toward anti-inflammatory vascular
enhancement. It may provide dynamic oxygenation throughout all dermal/epidermal
pathways.